Holen Sie sich die Stockscreener-App
43.37
1.84%
-0.8238
Schlusskurs vom Vortag:
$44.19
Offen:
$44.22
24-Stunden-Volumen:
438.21K
Relative Volume:
0.49
Marktkapitalisierung:
$1.69B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-63.78M
KGV:
-16.18
EPS:
-2.68
Netto-Cashflow:
$-53.91M
1W Leistung:
+10.76%
1M Leistung:
+225.17%
6M Leistung:
+254.11%
1J Leistung:
+170.27%
1-Tages-Spanne:
$42.88
$44.98
1-Wochen-Bereich:
$38.00
$44.98
52-Wochen-Spanne:
$7.575
$46.42
Celcuity Inc Stock (CELC) Company Profile
Firmenname
Celcuity Inc
Sektor
Branche
Telefon
763-392-0767
Adresse
16305 36TH AVENUE N, MINNEAPOLIS, MN
Vergleichen Sie CELC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
43.37 | 1.76B | 0 | -63.78M | -53.91M | -2.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
377.80 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.49 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.89 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
667.94 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
296.19 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-01 | Fortgesetzt | Stifel | Buy |
| 2024-07-22 | Eingeleitet | Leerink Partners | Outperform |
| 2024-02-22 | Eingeleitet | Stifel | Buy |
| 2023-12-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-09-07 | Eingeleitet | Jefferies | Buy |
| 2021-07-29 | Eingeleitet | Cowen | Outperform |
| 2021-07-27 | Eingeleitet | Needham | Buy |
| 2021-01-28 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-11 | Fortgesetzt | Craig Hallum | Buy |
| 2018-11-20 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Celcuity Inc Aktie (CELC) Neueste Nachrichten
Celcuity Announces Q2 2025 Earnings Date: Biotech's Financial Results and Conference Call Details Revealed - Stock Titan
Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call - GlobeNewswire
Celcuity Inc. shares rise 3.71% intraday as Novartis considers deal for biotech Avidity Biosciences. - AInvest
Celcuity’s Promising Clinical Trial Results and Strong Buy Recommendation by Andrew Berens - TipRanks
Celcuity Inc. Stock Analysis and ForecastCapitalize on market momentum for maximum gains - Jammu Links News
What drives Celcuity Inc. stock priceMaximize gains with expert analysis - Jammu Links News
What are analysts’ price targets for Celcuity Inc. in the next 12 monthsNavigate the market with precision tools - Jammu Links News
What are the technical indicators suggesting about Celcuity Inc.Unlock exclusive trading strategies - Jammu Links News
What is the risk reward ratio of investing in Celcuity Inc. stockPhenomenal returns - Jammu Links News
Should I hold or sell Celcuity Inc. stock in 2025Get expert analysis on top stock picks - Jammu Links News
How does Celcuity Inc. compare to its industry peersRapid return acceleration - Jammu Links News
Is it the right time to buy Celcuity Inc. stockBuild a winning investment portfolio - Jammu Links News
Why is Celcuity Inc. stock attracting strong analyst attentionAchieve rapid wealth accumulation through smart investing - Jammu Links News
What markets is Celcuity Inc. expanding into Is GSUN stock a good long term investment option - Jammu Links News
Celcuity Completes $201.25 Million Convertible Notes Issuance - MSN
What is the dividend policy of Celcuity Inc. stockExceptional risk-adjusted gains - Jammu Links News
What institutional investors are buying Celcuity Inc. stockSwing Trade Outlook For Every Investor - jammulinksnews.com
Celcuity Raises $248.7 Million Through Stock and Notes - The Globe and Mail
Celcuity announces $225M combined offerings; shares down - MSN
Celcuity Inc. stock trend outlook and recovery pathMarket Momentum Signal Generator Shows Trends - metal.it
Celcuity Inc. shares fall 1.57% after-hours as Novartis' Leqvio® receives FDA label update. - AInvest
Celcuity Inc's Recent Stock Offering: A Strategic Move in the Biotech Sector - AInvest
How strong is Celcuity Inc. company’s balance sheetSmart Portfolio Data Feed For 2025 - Jammu Links News
Celcuity prices $248.7M debt, stock offerings - MSN
Insiders Favor These 3 High Growth Companies - Yahoo Finance
Celcuity Inc. shares fall 1.24% after-hours following Novartis Canada's Scemblix approval expansion. - AInvest
Celcuity Surges 4.68% on $423.7M Capital Raise as $250M Volume Ranks 486th - AInvest
Dalvey David sells Celcuity (CELC) stock worth $4.8 million - Investing.com Australia
Dalvey David sells Celcuity (CELC) stock worth $4.8 million By Investing.com - Investing.com India
Celcuity: Positive Phase 3 Wild-Type ABC Data With Gedatolisib Leads To End Of 2025 Catalyst - Seeking Alpha
Celcuity Inc. Announces Pricing of Concurrent Public - GlobeNewswire
Celcuity (CELC) Is Up 176.2% After Positive Phase 3 Breast Cancer Results — Has the Bull Case Changed? - simplywall.st
Celcuity Prices Public Offering Of 175 Mln, 2.75% Sr. Notes, And 1.84 Mln Shares At $38/Shr - Nasdaq
Celcuity prices $175 million convertible notes, $85 million stock offering - Investing.com Australia
Celcuity prices $175 million convertible notes, $85 million stock offering By Investing.com - Investing.com India
Form FWP Celcuity Inc. Filed by: Celcuity Inc. - StreetInsider
Celcuity Updates Loan Agreement and Launches $225M Offering for Biotech Firm - AInvest
Celcuity Announces Concurrent Public Offerings to Raise $258.75 Million - AInvest
Is Celcuity Inc. stock a good hedge against inflationQuick Gain Stock Watch With Indicators Reviewed - metal.it
Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments - Benzinga
Up 215% YTD, Should You Grab This Growth Stock Before It’s Too Late? - Barchart.com
AI Trend Models Suggest Bounce for Celcuity Inc.Watchlist for Smart Swing Trading Updated - metal.it
Celcuity's triple drug combo tops AstraZeneca's treatment in breast cancer trial - MSN
Short Term Trend Reversal in Celcuity Inc. PossibleAI Based High Gain Watchlist Scanner Shared - metal.it
Celcuity Shares Double After Landmark Breast Cancer Drug Trial Results - MSN
Celcuity Surpasses Analyst Target Price, Shares Trade at $36.79 - AInvest
Relay Therapeutics has positive read from Celcuity data, says Barclays - The Globe and Mail
Celcuity (CELC) Skyrockets 167% on Breast Cancer Treatment Trial - Insider Monkey
Finanzdaten der Celcuity Inc-Aktie (CELC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):